- $8.24bn
- $8.38bn
- $2.09bn
- 88
- 17
- 100
- 76
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,125 | 1,834 | 2,063 | 2,035 | 2,086 |
Cost of Revenue | |||||
Gross Profit | 730 | 583 | 689 | 714 | 805 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 2,072 | 1,649 | 1,841 | 1,765 | 1,803 |
Operating Profit | 53 | 185 | 222 | 270 | 284 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 71.8 | 199 | 234 | 271 | 267 |
Provision for Income Taxes | |||||
Net Income After Taxes | 61.1 | 166 | 197 | 172 | 204 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 60.8 | 166 | 435 | 401 | 256 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 60.8 | 166 | 435 | 401 | 256 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 4.98 | 3.21 | 3.33 | 2.23 | 3.54 |
Dividends per Share |